Background This study transferred a recombinant gene encoding human insulin like growth factor-1 (hIGF-1) into modified primary skeletal myoblasts with a retroviral vector (pLgXSN ) and determined whether the hIGF-1 promoted growth of skeletal muscle in rat. Methods hIGF-1cDNA was amplified in vitro from normal human liver cells by using RT-PCR and cloned into plasmid vector pLgXSN. The recombinant vector pLghIGF-1SN and control vector pLgGFPSN were transfected into packaging cell PT67 and G418 was used to select positive colony. Myoblasts were infected with a high titre viral supernatant and transduction efficiency was evaluated as GFP expression. The expression of hIGF-1 mRNA in myoblasts was investigated by immunocytochemistry and RT-PCR. MTT assays detected the growth of myoblasts in vitro. Myoblasts transduced with pLghIGF-1SN were injected into hind limb muscles of 10-12 week male SD rats. Formed tissues were harvested 4 weeks later. Myocyte diameter, mean weight of hind limb and body were measured to evaluate the skeletal muscle growth. Results Recombinant retroviral plasmid vector pLghIGF-1SN was constructed successfully. The titre of the packaged recombinant retrovirus was 1×10 6 cfu/ml. The transfection rate of PT67 cells reached 100% after G418
uscle atrophy may occur in aging skeletal muscles, neurodegenerative syndromes, disease related cachexia and spaceflight. 1, 2 It is characterized by a loss of body mass, mainly skeletal muscles. Metabolic abnormalities develop in various chronic diseases and lead to progressive catabolism with decrements in the skeletal musculature that result in muscle atrophy. 2 Studies show that insulin like growth factor-1(IGF-1) plays a crucial role in the loss of muscle mass observed in catabolic states. 2 IGF-1 has a primary role in stimulating protein synthesis and promoting the proliferation and differentiation of muscle satellite cells. 2, 3 It can activate cell survival pathways, prevent cell death and restore muscle function.
and was attributed to inability to deliver the protein in a consistent manner. 6, 7 Schakman and Gilson 2 demonstrated that IGF-1 gene transferred into muscle using the plasmid pcDNA3.1-hIGF-1 under the mediation of electroporation prevented muscle atrophy in glucocorticoid treated rats. However, pcDNA3.1 vectors are characterized by a progressive loss of gene expression because they are not integrated into the host genome. Electrotransfer of pure DNA is a powerful tool for in vivo muscle transfection and a promising treatment of muscle disorders. 8 However, the migration of injected DNA into muscle by electrotransfer is very limited and muscle electroporation sometimes can cause injury. 8 The retroviruses are the only vectors that integrate their genes efficiently into the genome of the target cells and provide long term expression of the transgenes. 9 The transplantation of cultured myoblasts into mature skeletal muscle is the basis for a new therapeutic approach to muscle and nonmuscle diseases. 10 Genetically modified skeletal muscle myoblasts can be injected into muscle tissues to deliver proteins systemically or locally and provide long term, stable expression. 11, 12 Myoblast gene therapy in mice has been used successfully to deliver systemic factors recombinant human growth hormone(rhGH), factor IX, granulocyte colony stimulating factor and erythropoietin. 13 Therefore, we hypothesized that a recombinant gene encoding human insulin like growth factor-1, stably introduced into cultured myoblasts in a retroviral vector, might promote the growth of skeletal muscle. To test our hypothesis, we constructed retroviral vector containing hIGF-1 gene, transferred a recombinant gene encoding hIGF-1 into myoblasts with a retroviral vector and evaluated the effect of hIGF-1 delivered by genetically modified primary skeletal myoblasts on growth of skeletal muscle in rats. . Cells were added into 0.25% trypsin (Gibco) at 37˚C for 1 hour and filtered through 85 µm nylon mesh. Then the samples were centrifuged at 1000 rpm for 3 minutes to separate the dissociated cells. The pellet was resuspended in growth medium DMEM supplemented with 20% FBS and placed on dishes. Cells were purified with the method of different speed stick walls and incubated at 37˚C in 5% CO 2 .
METHODS

Cell lines and cell culture
Differentiation medium consisted of DMEM supplemented with 10 % horse serum. All media contained penicillin and streptomycin.
Design and synthesis of PCR primers
A pair of primers were designed and synthesized according to human IGF-1 cDNA sequences (GenBank). EcoR I and BamH I restriction sites were introduced into primers. The sequences of all primers used were: forward 5'-CGGAATTCATGCA-CACCATGTCCTCCT-3' (EcoR I site underlined), reverse 5'-CGGGATCCCTACATCCTGTAGTTCTT-GTT-3' (BamH I site underlined).
Gene amplification
Total RNA was extracted from samples of normal human livers with trizol reagent (Gibco) according to the manufacturer's directions. cDNA was synthesized at 42˚C with RNA as template. PCR was used to amplify hIGF-1cDNA fragments. The reaction system contained 1.5 µl of hIGF-1cDNA, 5.0 µl of 10×PCR buffer, 1 µl of 10 mmol/l of each of the four dNTPs, 4 µl of each of the two primers, 2.5 u Taq DNA polymerase (Promega, USA) made up to 50 µl final volume with sterile, doubly distilled water. PCR conditions were: denaturation (94˚C, 5 minutes); 30 cycles of denaturation (94˚C, 30 seconds), annealing (54˚C, 30 seconds), extension (72˚C, 45 seconds) and final extension (72˚C, 10 minutes). The PCR products were electrophoresed on a 1.5 % agarose gel. The amplified products were recovered and purified using DNA Purification kit (Zymo, USA) according to the manufacturer's instructions. 
Construction of recombinant retroviral plasmid vector
Both the amplified products and plasmid vector pLgXSN (5447 bp gift of Dusty Miller) were digested with restriction endonuclease EcoR I and BamH I (Promega) and linked with T4 DNA ligase (Promega).
The new recombinant plasmid vectors were transferred into the E Coli (DH5α) strain, prepared in small scale and analysed using restriction endonuclease analysis and DNA sequencing analysis. The colony identified was termed pLghIGF-1SN.
Packaging of recombinant retrovirus
PT67 packaging cells were seeded onto a 6-well plate at 1×10 5 cells per well and incubated for 24-48 hours. The cells were allowed to grow to 60%-70% confluence and then rinsed with fresh DMEM medium. The plasmid pLgGFPSN (provided by our laboratory) and pLghIGF-1SN were transfected into the packaging cell line PT67 with Fugene6 Transfection Reagent (Roche, USA) and incubated for 24 hours following the manufacturer's instructions. The mixture was replaced with fresh medium to stop transfection and the transfected PT67 cells were further cultured. Green fluorescence was observed under confocal microscope 48 hours after the transfection. Transfected PT67 cells were further cultured with G418 (400 mg/l) selecting medium. Viral medium was filtered through 0.45 µm filter and then stored at -80˚C. Viral titres were estimated indirectly by transfecting a known number of NIH/3T3 cells with different volumes of retroviral containing supernatant.
Myoblast immunocytochemistry identification
Myoblasts were fixed with 4% paraformaldehyde in PBS. The cells were then rinsed in PBS，incubated with the first antibody (antidesmin, Sigma) and then detected with SP kit (Sigma).
Retroviral infection of myoblast
Myoblasts in exponential growth were seeded onto a 6-well plate at 1×10 5 cells per well and incubated for 48 hours. The cells were allowed to grow to 80% confluence and medium removed. One milliliter supernatant of retrovirus containing 8 µg/ml polybrene (Sigma, USA) was added to each well. The mixtures were incubated for 12 hours when viral solutions were replaced with fresh medium to stop transfection. Two days after culturing, confocal microscopy was used to observe the expression of GFP and flow cytometry to detect the transfection rate in infected myoblasts and then myoblasts transfected with GFP and hIGF-1 gene were selected and further cultured. Two weeks later, flow cytometry was used to detect the transfection rate of fluorescence of myoblasts expressing GFP and immunocytochemistry to detect the expression of hIGF-1 in myoblasts.
Gene expression
Two weeks after transfection, total RNA was extracted separately from myoblast-IGF-1 (hIGF-1-transfected myoblasts), myoblast-GFP (GFPtransfected myoblasts) and myoblast (nontransfected myoblast). β-actin primers were used as an internal control. Expression of IGF-1 mRNA was detected by RT-PCR. The protocol of PCR reaction system was: denaturation (94˚C, 5 minutes); 30 cycles of denaturation (94˚C, 30 seconds), annealing (54˚C, 30 seconds) and extension (72˚C, 45 seconds); and final extension (72˚C, 7 minutes). RT-PCR products were electrophoresed on a 15 % agarose gel and photographs taken. The integral optical densities of the electrophoretic lanes containing hIGF-1 and β-actin in each group were detected by a GDS8000 pathology image processing system (Ultra-Violet Products, Cambridge, UK) and the ratio (integral optical density of IGF-1)/(integral optical density of β-actin) calculated. The calculated data represented the expression of IGF-1mRNA in each group. The sequences of the primers used were: hIGF-1(393 bp):
forward 5'-ATGCACACCATGTCCTCCT-CGCAT3', reverse 5'-CTACATCCTGTAGTTCTTGTT-3'; β-actin (764 bp): forward 5'-TTGTCACCAACTGGG-ACGATATGG-3, reverse 5-GATCTTGATCT-TCATGGTGCTAGG-3'.
Mitogenicity bioassay (MTT test)
A total of 200 µl myoblast-IGF-1, 200 µl myoblast-GFP-1 and 200 µl myoblast were seeded separately into 96-well plates every 24 hours for 5 days at a density of 1×10 6 cells per well. On the 6th day, 20 µl MTT (5 mg/ ml) was added to each well. The cells were further cultured for 4 hours when all liquid in each well was tipped out and 150 µl DMSO was added to dissolve the precipitate. Absorbance at 490 nm was determined by ELISA spectrometry (n=8).
In vivo experiment
Myoblast-IGF-1, myoblast-GFP or myoblast, 2×10 6 cells suspended in 100 µl PBS, were injected into the hind limb muscles of 10-12 week male SD rats (n = 12 for each cell type). Body weights were measured and blood was obtained after 4 weeks. IGF-1 levels in rat serum were measured with IGF-1 radioimmunoassay kits (Jiuding Medical & Bioengineering, Tianjin, China). At the end of the experiments, the rats were killed and hind limb muscles of the rats were removed by disarticulating the femurs from the acetabulum at the hip, dissected, blotted, weighed then embedded in paraffin and sections stained with hematoxylin and eosin for measurements of muscle fibre diameter. Quantitative evaluation was carried out by morphometry. Muscle fibre diameter was measured using only cross sections that included a nuclear profile. A total of 50 cells per animal were evaluated.
Statistical analysis
Statistical analysis was done by SPSS 11.5. Parametric data are expressed as mean ± standard deviation. Statistical analyses were performed using one way ANOVA to compare muscles from different animals undergoing different experimental conditions or a paired t test to compare muscles undergoing different experimental conditions within the same animal. A P<0.05 was considered statistically significant.
RESULTS
Construction and identification recombinant plasmid
The recombinant retroviral plasmid vector was identified by restriction endonuclease analysis (Fig.1) and DNA sequence analysis. The results showed that the cDNA sequence of hIGF-1 was consistent with the sequence of GenBank. We concluded that the recombinant retroviral plasmid vector pLghIGF-1SN was constructed successfully.
Myoblast immunocytochemistry identification
Myoblasts were immunochemistry stained by desmin antibody 4 days after the primary culture. The results showed that 98% of myoblasts were desmin positive cells (Fig. 2) .
Retroviral infection of myoblast
The supernatant, containing recombinant retrovirus, above the PT67 packaging cells was used to infect NIH3T3 cells to determine viral titre. The results showed that the titre of packaged recombinant retrovirus pLghIGF-1SN was 1×10 6 infective viral grains/ml so primary myoblasts were infected by high titre viral supernatant. Two days after culturing, the green fluorescence could be observed under confocal microscope and the transfection rate detected by flow cytometry was 33% (Fig. 3) . Viral medium was replaced with G418 selection medium. Two weeks after selecting culture, the transfection rate reached 100%. Immunocytochemistry was used to detect the expression of hIGF-1 (Fig. 4) . The effective expression of GFP and hIGF-1 in myoblasts infected by recombinant retrovirus could last for 6 weeks.
Expression of IGF-1 mRNA in myoblast
The expression of hIGF-1 mRNA was detected by RT-PCR. The results showed that hIGF-1mRNA was stably expressed in myoblast-hIGF-1. There was no expression of hIGF-1 mRNA in myoblast-GFP or myoblast. The expression of β-actin in the three cell types was not obviously different (Fig. 5 ).
Human IGF-1 promotes proliferation of myoblast
The results of the MTT assays showed that the proliferation rate of myoblast-IGF-1 in vitro was greatly increased compared to that of myoblast-GFP or myoblast (P <0.05, Fig. 6 ). Human IGF-1 directly promotes the proliferation of myoblast cells in vitro.
Human IGF-1 promotes growth of skeletal muscle After injection of myoblasts into rat muscles, myoblast-IGF-1 secreted IGF-1 stably and persistently. Four weeks after injection, the serum concentration, mean weights of hind limb and body of rats injected with myoblast-IGF-1 cells were higher than that of rats injected with myoblast-GFP or myoblast. Morphometric examination of the histological samples demonstrated a significant increase of myocyte diameter in IGF-1 group compared with GFP and control group (P<0.05, Table) . Human IGF-1 could be detected in rat serum after 6 weeks. Human IGF-1 promotes the proliferation of myoblast and the growth of skeletal muscles.
DISCUSSION
We have demonstrated the stable hIGF-1 gene transfection of primary rat myoblasts mediated by retroviral vector and the generation of clonal secondary strains expresses large quantities of hIGF-1. Following implantation, these genetically engineered myoblasts directed the expression of pharmacologic levels of hIGF-1 in the sera of rats. In this work, a high rate of gene expression was reached by constant synthesis and release of rhIGF-1 from genetically engineered myoblasts. Human IGF-1 gene transfer using this method promoted proliferation of myoblasts and increased the expression of myoblasts IGF-1 mRNA, body weight, muscle mass and muscle fibre diameter. We found that ectopic expression of IGF-1 using this method stimulated muscle fibre hypertrophy significantly.
IGF-1 is a 70 amino acid peptide hormone produced primarily by the liver of adults in response to growth hormone (GH) secretion by the pituitary gland. IGF-1 is a 7.5 kDa structural homologue of insulin with multifunctional activities that affect many anabolic processes including promotion of cell growth, inhibition of apoptosis and induction of cell differentiation. 15, 16 IGF-1 as a central trophic growth factor required for the proliferation of myoblasts, the progression of myogenic differentiation and subsequent growth and hypertrophy of myofibres has been widely investigated. Experimental models of muscle growth and regeneration have implicated IGF-1 as an important mediator of anabolic pathways in skeletal muscle cells. 1, 17 In this study, we reported that constant, stable expression of IGF-1 significantly promoted postnatal muscle growth. Two hypotheses could explain the muscle anticatabolic effect of IGF-1. First, IGF-1 can stimulate proliferation, differentiation and fusion of satellite cells through myofibres, thereby stimulating hypertrophy. A second hypothesis is that IGF-1 can increase protein synthesis and inhibit apoptosis.
Retroviral vectors offer many advantages for gene transfer and expression. 18 Retroviruses integrate into the chromosomal DNA, so their genome is stable in the host cells and is inherited by their progeny. Accordingly, long term expression of a transduced gene can be achieved through retroviral mediated gene transfer. 19 Other advantages of this vector include its broad host range and the availability of packaging cell lines for the large scale production of high titre vectors. 20 In addition, genes encoding resistance to toxic drugs such as neomycin, puromycin and hygromycin have been widely used in retroviral vectors to aid in the identification of transduced cells in vitro. 21 In this study, IGF-1 cDNA from the liver cell was amplified and a recombinant retrovirus pLghIGF-1SN containing human IGF-1 gene was engineered and subsequently used to infect myoblasts. After G418 selection and cell cloning, a stable IGF-1 transfected, myoblastic cell line, myoblast-IGF-1 was created using retrovirus mediated gene transfer. Expression of IGF-1 in IGF-1-transfected myoblast was confirmed by immunocytochemical identification and RT-PCR. The use of retroviral vectors in our studies resulted in the stable integration of the hIGF-1 gene into the myoblast genome and long term expression when implanted in vivo. The effective expression of GFP and hIGF-1 in myoblasts infected by recombinant retrovirus could last for 6 weeks. In addition, the recombinant vector is not toxic to the cells: there were no biological characteristic changes in transduced cells.
Myoblast transplantation has been extensively studied as a gene complementation approach for genetic diseases. Myoblasts prepared from skeletal muscles can be grown in a large number in tissue culture. Implantation of cultured myoblasts into skeletal muscles can fuse with the existing host myofibres and the myoblast mediated gene transfer can deliver recombinant proteins into the systemic circulation. 11 In this study, myoblasts transduced with pLghIGF-1SN were injected into hind limb muscles. After injection into skeletal muscles, genetically engineered rat myoblasts efficiently fused with host myofibres and products of transgenes were transported into the systemic circulation 12 and produced an exogenous hIGF-1 gene product. Human IGF-1 could be detected in rat serum after 6 weeks. However, myoblast transplantation has disadvantages: immunesuppression of the host has been necessary for long term retention of transplanted cells. CsA treatment can eliminate immunesuppression. 13 In summary, a recombinant retrovirus encoding human IGF-1 exerts significant positive effects on growth of skeletal muscles. Genetically modified myoblasts provide a method of constant synthesis and release of rhIGF-1. Myoblast mediated IGF-1 gene therapy can provide a new option for the future clinical treatment of muscles diseases.
